Ryan Weispfenning News Today

MDT earnings call for the period ending March 31, 2024.

FINAL Q4 FY24 Earnings call commentary Ryan Weispfenning Good...

Closed-loop sensing capability instantly and automatically adjusts therapy while treating chronic pain DUBLIN, April 26, 2024 /PRNewswire/ -- Medtronic plc , a global leader in healthcare...

/PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for...

AI-driven solutions and strategic alliances showcase Medtronics promise to enhance the efficiency and effectiveness of endoscopy DUBLIN, April 10, 2024 /PRNewswire/ -- Medtronic plc , a global...

Despite prevalence of chronic conditions associated with aortic stenosis in women over 65, the majority have never been referred to a cardiologist; Racial disparities may present further opportunities...

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN...

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.